Interferon gamma biosimilar - Pharmaclon

Drug Profile

Interferon gamma biosimilar - Pharmaclon

Alternative Names: Ingaron

Latest Information Update: 12 Jun 2015

Price : $50

At a glance

  • Originator Pharmaclon
  • Class Antineoplastics; Interferons; Lymphokines
  • Mechanism of Action Immunomodulators; Immunostimulants; Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer; Chlamydial infections; Chronic granulomatous disease; Genital warts; Hepatitis B; Hepatitis C; Herpes zoster; Herpesvirus infections; HIV infections; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype; Prostatitis; Severe acute respiratory syndrome; Tuberculosis

Most Recent Events

  • 04 Jun 2015 Efficacy and adverse events data from clinical trials in Cancer released by Pharmaclon before June 2015
  • 04 Jun 2015 Efficacy and adverse events data from clinical trials in Herpes infection released by Pharmaclon before June 2015
  • 04 Jun 2015 Efficacy and adverse events data from clinical trials in Chlamydial infections released by Pharmaclon before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top